ESAM: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: ESAM

NCBI ID: G90952

ESAM

ESAM: A Potential Drug Target Or Biomarker for Various Diseases

ESAM, or Endothelial cell-selective adhesion molecule, is a protein that is expressed in endothelial cells, which are the cells that line the blood vessels. These cells play a crucial role in maintaining blood pressure and ensuring that oxygen and nutrients are delivered to tissues throughout the body.

Recent studies have identified ESAM as a potential drug target or biomarker for a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. In this article, we will explore the biology and potential applications of ESAM in more detail.

ESAM is a transmembrane protein that is composed of four extracellular domains: a N-terminus, a T-terminus, a middle domain, and an C-terminus. The N-terminus of ESAM is responsible for its cell surface expression, while the T-terminus is involved in its cell-cell adhesion. The middle domain contains the protein's unique features, such as its ability to interact with heparin, a protein that is often used in drug development as a signaling molecule. The C-terminus is responsible for the protein's stability and can be involved in its intracellular signaling.

ESAM is a potent adhesion molecule that can interact with various cell types, including endothelial cells, epithelial cells, and fibroblasts. Its interactions with these cells are critical for tissue repair and regeneration, as well as for the development and maintenance of tissues such as blood vessels, lungs, and hearts.

One of the most promising applications of ESAM is as a drug target for cancer. ESAM has been shown to be highly expressed in a variety of cancer tissues, including breast cancer, lung cancer, and colon cancer. Its interaction with heparin also makes it a potential target for anti-inflammatory therapies, which can be effective in reducing the risk of cancer progression.

In addition to its potential as a cancer drug, ESAM has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in a variety of diseases, including neurodegenerative disorders, cardiovascular disease, and liver disease. This suggests that ESAM may be a useful diagnostic or prognostic tool for these diseases.

ESAM's ability to interact with heparin also makes it a potential target for other therapies, such as those used to treat autoimmune diseases. By inhibiting ESAM's adhesion capabilities, these therapies may be able to reduce inflammation and improve tissue repair.

Another potential application of ESAM is its role in tissue repair and regeneration. ESAM's interactions with heparin allow it to play a role in the development of new tissues, such as blood vessels and heart tissue. This may have potential applications in the treatment of tissue engineering and regenerative medicine.

In conclusion, ESAM is a protein that has been identified as a potential drug target or biomarker for a variety of diseases. Its interactions with heparin and its ability to interact with different cell types make it a promising target for therapies aimed at reducing inflammation, improving tissue repair and regeneration, and treating a variety of diseases. Further research is needed to fully understand the biology and potential applications of ESAM, and to develop safe and effective therapies based on its properties.

Protein Name: Endothelial Cell Adhesion Molecule

Functions: Can mediate aggregation most likely through a homophilic molecular interaction

The "ESAM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESAM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets